Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorena Rami

Showing results (81-90 of 115) with videos related to

Pageof 12
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 16, 2018
Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease-Data from three memory clinic studiesXiaochen Hu, Charlotte E Teunissen, Annika Spottke, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 9, 2016
Implementation of subjective cognitive decline criteria in research studiesJosé L Molinuevo, Laura A Rabin, Rebecca Amariglio, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2018
Wishes and preferences for an online lifestyle program for brain health-A mixed methods studyLinda M P Wesselman, Ann-Katrin Schild, Nina Coll-Padros, et al.
Alzheimer'S Research & Therapy|April 17, 2019
Personalized risk for clinical progression in cognitively normal subjects-the ABIDE projectIngrid S van Maurik, Rosalinde E R Slot, Sander C J Verfaillie, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive DeclineSimone Lista, Jose L Molinuevo, Enrica Cavedo, et al.
Molecular & Cellular Proteomics : MCP|January 5, 2019
Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal FluidAlberto Lleó, Raúl Núñez-Llaves, Daniel Alcolea, et al.
Scientific Reports|June 5, 2024
Cognitive profile, neuroimaging and fluid biomarkers in post-acute COVID-19 syndromeNúria Guillén, Agnès Pérez-Millan, Neus Falgàs, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|January 9, 2019
Computer-assisted prediction of clinical progression in the earliest stages of ADHanneke F M Rhodius-Meester, Hilkka Liedes, Juha Koikkalainen, et al.
Alzheimer'S Research & Therapy|January 19, 2019
Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samplesSteffen Wolfsgruber, José Luis Molinuevo, Michael Wagner, et al.
EMBO Molecular Medicine|March 5, 2016
sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markersMarc Suárez-Calvet, Gernot Kleinberger, Miguel Ángel Araque Caballero, et al.
Pageof 12

Showing results (81-90 of 115) with videos related to

Sort By:
Pageof 12
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 16, 2018
Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease-Data from three memory clinic studiesXiaochen Hu, Charlotte E Teunissen, Annika Spottke, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 9, 2016
Implementation of subjective cognitive decline criteria in research studiesJosé L Molinuevo, Laura A Rabin, Rebecca Amariglio, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2018
Wishes and preferences for an online lifestyle program for brain health-A mixed methods studyLinda M P Wesselman, Ann-Katrin Schild, Nina Coll-Padros, et al.
Alzheimer'S Research & Therapy|April 17, 2019
Personalized risk for clinical progression in cognitively normal subjects-the ABIDE projectIngrid S van Maurik, Rosalinde E R Slot, Sander C J Verfaillie, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive DeclineSimone Lista, Jose L Molinuevo, Enrica Cavedo, et al.
Molecular & Cellular Proteomics : MCP|January 5, 2019
Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal FluidAlberto Lleó, Raúl Núñez-Llaves, Daniel Alcolea, et al.
Scientific Reports|June 5, 2024
Cognitive profile, neuroimaging and fluid biomarkers in post-acute COVID-19 syndromeNúria Guillén, Agnès Pérez-Millan, Neus Falgàs, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|January 9, 2019
Computer-assisted prediction of clinical progression in the earliest stages of ADHanneke F M Rhodius-Meester, Hilkka Liedes, Juha Koikkalainen, et al.
Alzheimer'S Research & Therapy|January 19, 2019
Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samplesSteffen Wolfsgruber, José Luis Molinuevo, Michael Wagner, et al.
EMBO Molecular Medicine|March 5, 2016
sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markersMarc Suárez-Calvet, Gernot Kleinberger, Miguel Ángel Araque Caballero, et al.
Pageof 12